New Delhi has moved to close one of the longest standing gaps in India’s drug safety net. Under a draft proposal published on Wednesday, 4 November 2026, a drug manufacturing licence would be suspended immediately when government testing finds that a medicine fails specified quality standards, instead of waiting for the slow exchange of show-cause notices that currently comes first.
The change matters because of what happens during that wait. Today, regulators must issue a show-cause notice before they suspend or cancel a licence. The Health Ministry says that process creates a time lag between a drug being declared “not of standard quality” and any action against it. In that interval, the medicine can stay in circulation, patients can keep taking it, and an effective recall becomes harder to carry out.
The draft, dated 28 October but published on 4 November, is now open for objections and suggestions for 30 days. The final rules would take effect only after publication in the Official Gazette.
What would trigger an instant suspension
The proposal covers failures found in government testing across four critical parameters. A licence would face immediate suspension if a drug fails on impurities, sterility, assay, or dissolution. Assay measures how much active ingredient a medicine actually contains, while dissolution tests how it releases that ingredient in the body. Both go to the heart of whether a drug works as prescribed.
In plainer terms, the net covers medicines that are sub-potent or over-potent, that dissolve improperly and lose therapeutic effect, that contain unapproved chemical variants or degradation products, or that carry toxic contaminants or microbial contamination in injectables, eye drops and other sterile formulations. These are not paperwork lapses. They are the failures that can make treatment ineffective or unsafe.
How a licence would be restored
Suspension under the proposal would not lift on its own. The licence would stay suspended until the manufacturer carries out an effective root-cause analysis and puts corrective and preventive action, known as CAPA, in place to the regulator’s satisfaction.
Restoration would follow verification, not just a promise. Regulators would need to be satisfied that the corrective measures have actually been implemented, with on-site verification and approval by the relevant licensing authority before the suspension is revoked. The factory would have to show its fix, not merely describe it.
The draft also tightens the information chain, letting the central licensing authority seek a manufacturer’s investigation reports and corrective measures, along with details of action taken by state regulators.
Everyone gets the test report at once
Another part of the proposal rewrites how test results travel. Amendments to Form 13, the Government Analyst’s test report, would ensure simultaneous reporting to the Drugs Controller General of India, the relevant state or Union Territory licensing authority, and both the manufacturer and the marketer named on the label.
That single change is designed to stop a familiar problem: one authority acting while another is still waiting for the paperwork. When every party receives the same report at the same time, there is less room for a failed batch to keep moving through the supply chain while officials catch up.
The overhaul follows recommendations from the Drugs Consultative Committee and the Drugs Technical Advisory Board.
Why scrutiny has sharpened
India is one of the world’s largest pharmaceutical manufacturers, and its quality standards have faced closer scrutiny in recent years. Locally made cough syrups were linked to the deaths of children in India and in countries including Gambia and Uzbekistan, cases that put Indian drug regulation under an international spotlight.
More recently, the regulator ordered Sun Pharmaceutical Industries, the country’s largest drugmaker by revenue, to stop manufacturing, selling and distributing ophthalmic products made at its Assam facility after finding failures in its quality management system.
What happens next
- Draft published: 4 November 2026, with the draft itself dated 28 October.
- Consultation window: objections and suggestions within 30 days of publication.
- Trigger: government testing failure on impurities, sterility, assay or dissolution.
- Restoration: only after root-cause analysis, corrective action and regulator verification.
- Effect: final rules take effect on publication in the Official Gazette.
Frequently asked questions
Does every failed drug test lead to instant suspension? No. The proposal applies to specified quality failures, including impurities, sterility, assay and dissolution, rather than every minor deviation.
Is the rule already in force? No. It is a draft published on 4 November 2026, and it takes effect only after consultation and final publication in the Official Gazette.
How can a manufacturer get its licence back? By completing a root-cause analysis, implementing corrective and preventive action, and passing regulator verification. The suspension is not lifted automatically.
Who receives the government test report? Under the proposed Form 13 changes, the report would go simultaneously to the Drugs Controller General of India, the state or Union Territory licensing authority, and the manufacturer and marketer on the label.
The consultation window is the moment for the industry and the public to shape the final rule. What survives it will say a lot about how seriously India intends to treat a failed drug test: as a paperwork dispute, or as a stop signal.
